Back to Search
BENJAMIN DJULBEGOVIC, MD
MD
Hematology (Internal Medicine) Physician
NPI: 1649201740IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
ME77998(FL)
Hematology (Internal Medicine) PhysicianPrimary
Internal Medicine — Hematology
Code: 207RH0000X
C151810(CA)ME77998(FL)
Hematology & Oncology Physician
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
89329(SC)
Education
OTHER
Class of 1976
Research & Publications (20)
Impact of quality of evidence on the strength of recommendations: an empirical study.
PMID 19622148·BMC Health Serv Res·2009
8-other
When should potentially false research findings be considered acceptable?
PMID 17326703·PLoS Med·2007
8-other
Evidence and decision making. Commentary on M.R. Tonelli (2006), Integrating evidence into clinical practice: an alternative approach to evidence-based approaches. Journal of Evaluation in Clinical Practice 12, 248-256.
PMID 16722903·J Eval Clin Pract·2006
8-other
What kind of evidence do patients and practitioners need: evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms.
PMID 16914268·Cancer Treat Rev·2006
8-other
At what degree of belief in a research hypothesis is a trial in humans justified?
PMID 12180373·J Eval Clin Pract·2002
8-other
Acknowledgment of uncertainty: a fundamental means to ensure scientific and ethical validity in clinical research.
PMID 11489238·Curr Oncol Rep·2001
8-other
Evaluation and appraisal of randomized controlled trials in myeloma.
PMID 11822763·Ann Oncol·2001
8-other
Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2).
PMID 19580665·Trials·2009
8-other
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.
PMID 19588423·Cochrane Database Syst Rev·2009
1-meta
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.
PMID 19074748·Ann Oncol·2009
3-trial
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate.
PMID 19458059·Clin Cancer Res·2009
8-other
Risk prediction versus diagnosis: preserving clinical nuance in a binary world.
PMID 19189922·Ann Intern Med·2009
8-other
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.
PMID 19410717·Lancet·2009
1-meta
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
PMID 19414675·J Clin Oncol·2009
3-trial
Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.
PMID 19141779·J Natl Cancer Inst·2009
1-meta
Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review.
PMID 19589478·Biol Blood Marrow Transplant·2009
4-observational
Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis.
PMID 19660713·Biol Blood Marrow Transplant·2009
1-meta
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 171 ASHLEY AVE
CHARLESTON, SC 29425 - Phone
- (843) 792-1414
Quick Facts
- NPI
- 1649201740
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 4
- Locations
- 2
- Years in Practice
- 50
- Publications
- 20
Are you this provider?
Claim Your Profile